vs
CapsoVision, Inc（CV）与FONAR CORP（FONR）财务数据对比。点击上方公司名可切换其他公司
FONAR CORP的季度营收约是CapsoVision, Inc的7.2倍（$25.5M vs $3.5M）。FONAR CORP净利率更高（8.0% vs -223.9%，领先231.9%）。FONAR CORP自由现金流更多（$-227.0K vs $-5.7M）
CapsoVision, Inc.是一家医疗科技企业，专注研发、生产先进胶囊内窥镜系统及配套诊断解决方案，旗下非侵入式胃肠道成像产品供应全球多地的医院、消化科诊所及医疗专业人员，助力提升消化道疾病检测准确率与患者诊疗体验。
FONAR是一家专业医疗技术企业，专注于设计、制造及销售包括立式、开放式在内的创新磁共振成像（MRI）设备，主要服务美国的医院、影像诊断中心及医疗机构，为临床诊断提供高精度扫描解决方案。
CV vs FONR — 直观对比
营收规模更大
FONR
是对方的7.2倍
$3.5M
净利率更高
FONR
高出231.9%
-223.9%
自由现金流更多
FONR
多$5.5M
$-5.7M
损益表 — Q3 2025 vs Q2 2026
| 指标 | | |
|---|---|---|
| 营收 | $3.5M | $25.5M |
| 净利润 | $-7.9M | $2.1M |
| 毛利率 | 54.1% | — |
| 营业利润率 | -226.7% | 13.5% |
| 净利率 | -223.9% | 8.0% |
| 营收同比 | — | 2.4% |
| 净利润同比 | — | 4.7% |
| 每股收益（稀释后） | $-0.17 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CVFONR
| Q4 25 | — | $25.5M | ||
| Q3 25 | $3.5M | $26.0M | ||
| Q2 25 | $3.3M | $27.3M | ||
| Q1 25 | — | $27.2M | ||
| Q4 24 | — | $24.9M | ||
| Q3 24 | — | $25.0M | ||
| Q2 24 | — | $25.9M | ||
| Q1 24 | — | $25.7M |
净利润CVFONR
| Q4 25 | — | $2.1M | ||
| Q3 25 | $-7.9M | $2.3M | ||
| Q2 25 | $-4.6M | $729.3K | ||
| Q1 25 | — | $2.5M | ||
| Q4 24 | — | $2.0M | ||
| Q3 24 | — | $3.1M | ||
| Q2 24 | — | $830.4K | ||
| Q1 24 | — | $1.9M |
毛利率CVFONR
| Q4 25 | — | — | ||
| Q3 25 | 54.1% | — | ||
| Q2 25 | 54.6% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率CVFONR
| Q4 25 | — | 13.5% | ||
| Q3 25 | -226.7% | 14.1% | ||
| Q2 25 | -140.3% | 5.3% | ||
| Q1 25 | — | 15.2% | ||
| Q4 24 | — | 11.9% | ||
| Q3 24 | — | 21.0% | ||
| Q2 24 | — | 7.4% | ||
| Q1 24 | — | 16.8% |
净利率CVFONR
| Q4 25 | — | 8.0% | ||
| Q3 25 | -223.9% | 8.7% | ||
| Q2 25 | -139.5% | 2.7% | ||
| Q1 25 | — | 9.2% | ||
| Q4 24 | — | 7.9% | ||
| Q3 24 | — | 12.6% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 7.3% |
每股收益（稀释后）CVFONR
| Q4 25 | — | — | ||
| Q3 25 | $-0.17 | — | ||
| Q2 25 | $-2.02 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $121.0K |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $20.4M | $176.9M |
| 总资产 | $25.7M | $217.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CVFONR
| Q4 25 | — | $121.0K | ||
| Q3 25 | — | $122.0K | ||
| Q2 25 | — | $56.5M | ||
| Q1 25 | — | $123.0K | ||
| Q4 24 | — | $121.0K | ||
| Q3 24 | — | $136.0K | ||
| Q2 24 | — | $56.5M | ||
| Q1 24 | — | $134.0K |
总债务CVFONR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $66.9K | ||
| Q1 24 | — | — |
股东权益CVFONR
| Q4 25 | — | $176.9M | ||
| Q3 25 | $20.4M | $174.9M | ||
| Q2 25 | $-139.0M | $172.6M | ||
| Q1 25 | — | $171.9M | ||
| Q4 24 | — | $169.8M | ||
| Q3 24 | — | $168.7M | ||
| Q2 24 | — | $166.0M | ||
| Q1 24 | — | $165.8M |
总资产CVFONR
| Q4 25 | — | $217.2M | ||
| Q3 25 | $25.7M | $218.4M | ||
| Q2 25 | $9.5M | $216.9M | ||
| Q1 25 | — | $214.9M | ||
| Q4 24 | — | $208.0M | ||
| Q3 24 | — | $212.3M | ||
| Q2 24 | — | $214.2M | ||
| Q1 24 | — | $209.6M |
负债/权益比CVFONR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.7M | $171.0K |
| 自由现金流经营现金流 - 资本支出 | $-5.7M | $-227.0K |
| 自由现金流率自由现金流/营收 | -160.5% | -0.9% |
| 资本支出强度资本支出/营收 | 0.3% | 1.6% |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | $5.7M |
8季度趋势，按日历期对齐
经营现金流CVFONR
| Q4 25 | — | $171.0K | ||
| Q3 25 | $-5.7M | $1.7M | ||
| Q2 25 | $-9.5M | $4.2M | ||
| Q1 25 | — | $3.1M | ||
| Q4 24 | — | $2.2M | ||
| Q3 24 | — | $1.7M | ||
| Q2 24 | — | $4.6M | ||
| Q1 24 | — | $2.8M |
自由现金流CVFONR
| Q4 25 | — | $-227.0K | ||
| Q3 25 | $-5.7M | $-177.0K | ||
| Q2 25 | $-9.6M | $3.6M | ||
| Q1 25 | — | $2.6M | ||
| Q4 24 | — | $1.5M | ||
| Q3 24 | — | $-148.0K | ||
| Q2 24 | — | $4.2M | ||
| Q1 24 | — | $2.6M |
自由现金流率CVFONR
| Q4 25 | — | -0.9% | ||
| Q3 25 | -160.5% | -0.7% | ||
| Q2 25 | -289.0% | 13.1% | ||
| Q1 25 | — | 9.4% | ||
| Q4 24 | — | 6.0% | ||
| Q3 24 | — | -0.6% | ||
| Q2 24 | — | 16.1% | ||
| Q1 24 | — | 10.2% |
资本支出强度CVFONR
| Q4 25 | — | 1.6% | ||
| Q3 25 | 0.3% | 7.2% | ||
| Q2 25 | 2.1% | 2.4% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | 3.0% | ||
| Q3 24 | — | 7.2% | ||
| Q2 24 | — | 1.6% | ||
| Q1 24 | — | 0.7% |
现金转化率CVFONR
| Q4 25 | — | 0.08× | ||
| Q3 25 | — | 0.75× | ||
| Q2 25 | — | 5.79× | ||
| Q1 25 | — | 1.26× | ||
| Q4 24 | — | 1.14× | ||
| Q3 24 | — | 0.53× | ||
| Q2 24 | — | 5.54× | ||
| Q1 24 | — | 1.50× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CV
暂无分部数据
FONR
| Managementof Diagnostic Imaging Centers | $23.2M | 91% |
| Manufacturingand Servicingof Medical Equipment | $2.4M | 9% |
